

NATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE

Single Technology Appraisal

Ipilimumab for previously untreated unresectable malignant melanoma

Matrix of consultees and commentators

Consultees	Commentators (no right to submit or appeal)
<p><u>Manufacturers/sponsors</u></p> <ul style="list-style-type: none"> • Bristol-Myers Squibb (ipilimumab) <p><u>Patient/carer groups</u></p> <ul style="list-style-type: none"> • Action for Children • Action for Sick Children • Afiya Trust • Black Health Agency • Cancer 52 • Cancer Black Care • Cancer Equality • Children's Society • CLIC Sargent • Counsel and Care • Equalities National Council • Factor 50 • Helen Rollason Heal Cancer Charity • Help Adolescents with Cancer • Macmillan Cancer Support • Maggie's Centres • Marie Curie Cancer Care • Muslim Council of Britain • Muslim Health Network • National Alliance of Childhood Cancer Patient Organisations • National Children's Bureau • Rarer Cancers Foundation • Skcin - Karen Clifford Skin Cancer Charity • Skin Care Campaign • South Asian Health Foundation • Specialised Healthcare Alliance • Teenage Cancer Trust • Tenovus • Together for Short Lives • Well Child <p><u>Professional groups</u></p> <ul style="list-style-type: none"> • British Association for Services to the Elderly 	<p><u>General</u></p> <ul style="list-style-type: none"> • Allied Health Professional Federation • Board of Community Health Councils in Wales • British National Formulary • Care Quality Commission • Department of Health, Social Services and Public Safety for Northern Ireland • Healthcare Improvement Scotland • Medicines and Healthcare products Regulatory Agency • National Association of Primary Care • NHS Alliance • NHS Commercial Medicines Unit • NHS Confederation • Public Health Wales NHS • Scottish Medicines Consortium <p><u>Comparator manufacturer(s)</u></p> <ul style="list-style-type: none"> • Bayer (dacarbazine) • Medac UK (dacarbazine) • PLIVA Pharma (dacarbazine) • Roche (vemurafenib) <p><u>Relevant research groups</u></p> <ul style="list-style-type: none"> • British Society for Dermatological Surgery • Cochrane Skin Group, Centre of Evidence-based Dermatology, University of Nottingham • Institute of Cancer Research • MRC Clinical Trials Unit • Melanoma Study Group • Myfanwy Townsend Melanoma Research Fund • National Cancer Research Institute • National Cancer Research Network • Research Institute of the Care of Older People • Skin Cancer Research Fund

Consultees	Commentators (no right to submit or appeal)
<ul style="list-style-type: none"> • British Association of Dermatologists • British Association of Skin Cancer Specialist • British Dermatological Nursing Group • British Geriatrics Society • British Institute for Radiology • British Psychosocial Oncology Society • British Skin Foundation • Cancer Networks Pharmacists Forum • Cancer Research UK • National Pharmacy Association • Primary Care Dermatology Society • Royal College of General Practitioners • Royal College of Nursing • Royal College of Pathologists • Royal College of Physicians • Royal College of Radiologists • Royal Pharmaceutical Society • Royal Society of Medicine • Society and College of Radiographers • United Kingdom Clinical Pharmacy Association • United Kingdom Oncology Nursing Society <p><u>Others</u></p> <ul style="list-style-type: none"> • Bedfordshire and Luton PCT Cluster • Department of Health • Welsh Government • West Mercia PCT Cluster 	<ul style="list-style-type: none"> • Skin Research Centre • Skin Treatment & Research Trust <p><u>Evidence Review Group</u></p> <ul style="list-style-type: none"> • National Institute for Health Research Health Technology Assessment Programme • NHS Centre for Reviews & Dissemination and Centre for Health Economics -York <p><u>Associated Guideline Groups</u></p> <ul style="list-style-type: none"> • National Collaborating Centre for Cancer <p><u>Associated Public Health Groups</u></p> <ul style="list-style-type: none"> • None

NICE is committed to promoting equality, eliminating unlawful discrimination and fostering good relations between people who share a protected characteristic and those who do not. Please let us know if we have missed any important organisations from the lists in the matrix, and which organisations we should include that have a particular focus on relevant equality issues.

PTO FOR DEFINITIONS OF CONSULTEES AND COMMENTATORS

Definitions:

Consultees

Organisations that accept an invitation to participate in the appraisal; the manufacturer(s) or sponsor(s) of the technology; national professional organisations; national patient organisations; the Department of Health and the Welsh Government and relevant NHS organisations in England.

The manufacturer/sponsor of the technology is invited to make an evidence submission, respond to consultations, nominate clinical specialists and has the right to appeal against the Final Appraisal Determination (FAD).

All non-manufacturer/sponsor consultees are invited to submit a statement¹, respond to consultations, nominate clinical specialists or patient experts and have the right to appeal against the Final Appraisal Determination (FAD).

Commentators

Organisations that engage in the appraisal process but that are not asked to prepare an evidence submission or statement, are able to respond to consultations and they receive the FAD for information only, without right of appeal. These organisations are: manufacturers of comparator technologies;

Healthcare Improvement Scotland ; the relevant National Collaborating Centre (a group commissioned by the Institute to develop clinical guidelines); other related research groups where appropriate (for example, the Medical Research Council [MRC], National Cancer Research Institute); other groups (for example, the NHS Confederation, NHS Alliance and NHS Commercial Medicines Unit, and the *British National Formulary*).

All non-manufacturers/sponsors commentators are invited to nominate clinical specialists or patient experts.

Evidence Review Group (ERG)

An independent academic group commissioned by the National Institute for Health Research (NIHR) Health Technology Assessment Programme (HTA Programme) to assist the Appraisal Committee in reviewing the manufacturer/sponsor evidence submission to the Institute.

¹ Non manufacturer consultees are invited to submit statements relevant to the group they are representing.